Structure via PubChem · Public domain (PubChem)
idebenone
Sign in to saveAlso known as 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione, 2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone, 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone, CV 2619, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone, BRN 2001459, 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-p-benzoquinone
Idebenone, sold under the brand name Raxone among others, is a medication that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. the drug is not approved for these indications in North America or Europe. It is approved by the European Medic
Chemical data
- Formula
- C19H30O5
- Molecular weight
- 338.4 g/mol
- IUPAC name
- 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
- SMILES
- CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO
- InChIKey
- JGPMMRGNQUBGND-UHFFFAOYSA-N
- XLogP
- 4.3
- Polar surface area
- 72.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2015
- Indications
- MELAS, primary progressive multiple sclerosis, attention deficit hyperactivity disorder, non-alcoholic fatty liver disease
via ChEMBL · EBI
Research
850 papers- Idebenone: Clinical Potential Beyond Neurological Diseases.Drug design, development and therapy · 2025
- Idebenone: When an antioxidant is not an antioxidant.Redox biology · 2021
- Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial.Cell reports. Medicine · 2024
- Idebenone in Friedreich's ataxia.Expert opinion on pharmacotherapy · 2008
- Idebenone vs. rAAV2-ND4 gene therapy in the treatment of Leber's hereditary optic neuropathy: An indirect comparison meta-analysis.Indian journal of ophthalmology · 2025
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Mass
- 338.209324
- Has use
- medication
Show 6 more facts
- chemical formula
- C₁₉H₃₀O₅
- canonical SMILES
- CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO
- World Health Organisation international non-proprietary name
- idebenone
- defined daily dose
- 0.9
- subject has role
- antioxidant
- Commons category
- Idebenone
Sources (6)
via Wikidata · CC0
~5 min read
Encyclopedic overview
12 sectionsContents
- Uses
- Indications that are or were approved in some territories
- Nootropic effects and Alzheimer's disease
- Friedreich's ataxia (Sovrima)
- Leber's hereditary optic neuropathy (Raxone)
- Indications being explored
- Duchenne muscular dystrophy (Catena)
- Other neuromuscular diseases
- Life style
- Pharmacology
- Pharmacokinetics
- References
Idebenone, sold under the brand name Raxone among others, is a medication that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. the drug is not approved for these indications in North America or Europe. It is approved by the European Medicines Agency (EMA) for use in Leber's hereditary optic neuropathy (LHON) and was designated an orphan drug in 2007.
Chemically, idebenone is an organic compound of the quinone family. It is also promoted commercially as a synthetic analog of coenzyme Q10 (CoQ10).
Excerpted from Wikipedia’s “idebenone” article, available under the CC BY-SA 4.0 licence.